

A change of strategy in the war on cancer

Nature

459, 508-509

DOI: [10.1038/459508a](https://doi.org/10.1038/459508a)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Environmental-mediated drug resistance: a target for multiple myeloma therapy. <i>Expert Review of Hematology</i> , 2009, 2, 649-662.	1.0	38
3	Lessons from Applied Ecology: Cancer Control Using an Evolutionary Double Bind. <i>Cancer Research</i> , 2009, 69, 7499-7502.	0.4	132
5	For cancer, seek and destroy or live and let live?. <i>Nature</i> , 2009, 460, 324-324.	13.7	17
7	Cyanobacterial Cyclopeptides as Lead Compounds to Novel Targeted Cancer Drugs. <i>Marine Drugs</i> , 2010, 8, 629-657.	2.2	68
8	A theoretical quantitative model for evolution of cancer chemotherapy resistance. <i>Biology Direct</i> , 2010, 5, 25.	1.9	69
9	The evolutionary mechanism of cancer. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 1072-1084.	1.2	74
10	Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. <i>Journal of Internal Medicine</i> , 2010, 267, 515-525.	2.7	92
11	Interfering with RAS effector protein interactions prevent RAS-dependent tumour initiation and causes stop start control of cancer growth. <i>Oncogene</i> , 2010, 29, 6064-6070.	2.6	59
12	2009 Nobel Prize in physiology and medicine awarded for an enzyme in cancer. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 75-77.	0.9	1
13	Therapy-Induced Senescence in Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1536-1546.	3.0	650
14	Melanoma – An Unlikely Poster Child for Personalized Cancer Therapy. <i>New England Journal of Medicine</i> , 2010, 363, 876-878.	13.9	70
15	Anti-Angiogenic Therapies for Children with Cancer. <i>Current Cancer Drug Targets</i> , 2010, 10, 879-889.	0.8	6
16	Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations. <i>Current Medicinal Chemistry</i> , 2010, 17, 1635-1678.	1.2	76
17	Proton dynamics in cancer. <i>Journal of Translational Medicine</i> , 2010, 8, 57.	1.8	97
18	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. <i>European Journal of Cancer</i> , 2010, 46, 2166-2177.	1.3	71
19	Effects of herbal products on the metabolism and transport of anticancer agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1195-1213.	1.5	56
20	Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. <i>Lancet Oncology</i> , The, 2010, 11, 465-475.	5.1	79
21	H ₂ O ₂ -mediated Cytotoxicity of Pharmacologic Ascorbate Concentrations to Neuroblastoma Cells: Potential Role of Lactate and Ferritin. <i>Cellular Physiology and Biochemistry</i> , 2010, 25, 767-774.	1.1	55

#	ARTICLE	IF	CITATIONS
22	Supportive Cancer Care with Chinese Medicine. , 2010, , .		15
23	Integrated Imaging of Cancer Metabolism. Academic Radiology, 2011, 18, 929-931.	1.3	2
24	Neoplastic pericardial disease in lung cancer: Impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer, 2011, 72, 340-347.	0.9	44
25	Evolutionary Dynamics in Cancer Therapy. Molecular Pharmaceutics, 2011, 8, 2094-2100.	2.3	73
26	Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?. Future Oncology, 2011, 7, 385-394.	1.1	41
27	Targeted Therapies. , 2011, , .		4
29	Evolutionary Mechanisms and Diversity in Cancer. Advances in Cancer Research, 2011, 112, 217-253.	1.9	81
30	High-glycolytic cancers and their interplay with the body's glucose demand and supply cycle. Medical Hypotheses, 2011, 76, 157-165.	0.8	24
32	Approach to the treatment of multiple myeloma: a clash of philosophies. Blood, 2011, 118, 3205-3211.	0.6	137
33	Conciliation biology: the eco-evolutionary management of permanently invaded biotic systems. Evolutionary Applications, 2011, 4, 184-199.	1.5	94
34	Life is Physics: Evolution as a Collective Phenomenon Far From Equilibrium. Annual Review of Condensed Matter Physics, 2011, 2, 375-399.	5.2	194
35	Cancer: More of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer, 2011, 117, 440-445.	2.0	60
36	The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 10871-10877.	3.3	237
37	Looking at the Seemingly Contradictory Role of Vinblastine in Anaplastic Large-Cell Lymphoma From a Metronomic Perspective. Journal of Clinical Oncology, 2011, 29, e90-e91.	0.8	7
38	Computational Modeling of Tumor Response to Vascular-Targeting Therapies"Part I: Validation. Computational and Mathematical Methods in Medicine, 2011, 2011, 1-17.	0.7	36
39	Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches. Molecules, 2011, 16, 4408-4427.	1.7	20
40	Forty years on from Nixon's war, cancer research 'evolves'. Nature Medicine, 2011, 17, 757-757.	15.2	10
41	Control Dominating Subclones for Managing Cancer Progression and Posttreatment Recurrence by Subclonal Switchboard Signal: Implication for New Therapies. Stem Cells and Development, 2012, 21, 503-506.	1.1	25

#	ARTICLE	IF	CITATIONS
42	A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents. <i>Current Pharmaceutical Design</i> , 2012, 18, 1395-1406.	0.9	50
43	HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 4691-4701.	3.2	88
44	Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience. <i>Oncology</i> , 2012, 82, 249-260.	0.9	74
45	An Integrated Chemical Biology Approach Provides Insight into Cdk2 Functional Redundancy and Inhibitor Sensitivity. <i>Chemistry and Biology</i> , 2012, 19, 1028-1040.	6.2	36
46	What Do We Know 40 Years After Nixon Declared the "War on Cancer"? On the Origin, Prevention and Treatment of Cancer. <i>Journal of Cancer Education</i> , 2012, 27, 597-600.	0.6	4
47	Eruptive Squamous Cell Carcinomas Associated with BRAF-Inhibitor Therapy in a Patient with Metastatic Melanoma. <i>Dermatologic Surgery</i> , 2012, 38, 1086-1090.	0.4	2
48	'Go or Grow': the key to the emergence of invasion in tumour progression?. <i>Mathematical Medicine and Biology</i> , 2012, 29, 49-65.	0.8	281
49	Intratumor Heterogeneity: Evolution through Space and Time. <i>Cancer Research</i> , 2012, 72, 4875-4882.	0.4	844
50	Cancer research, a field on the verge of a paradigm shift?. <i>Trends in Molecular Medicine</i> , 2012, 18, 299-303.	3.5	13
51	The future of glioma treatment: stem cells, nanotechnology and personalized medicine. <i>Future Oncology</i> , 2012, 8, 1149-1156.	1.1	19
52	Maintenance therapy in solid tumors. <i>Community Oncology</i> , 2012, 9, 247-258.	0.2	0
53	On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1 α , and miR-210. <i>Frontiers in Pharmacology</i> , 2012, 3, 134.	1.6	35
54	Can We Discover "Really Safe and Effective" Anticancer Drugs?. <i>Advances in Pharmacoeconomics & Drug Safety</i> , 2012, 01, .	0.1	3
55	Managing drug resistance in cancer: lessons from HIV therapy. <i>Nature Reviews Cancer</i> , 2012, 12, 494-501.	12.8	150
56	Nanoparticles for cancer therapy using magnetic forces. <i>Nanomedicine</i> , 2012, 7, 447-457.	1.7	77
57	Fighting against cancer by integrative medicine. <i>Chinese Journal of Integrative Medicine</i> , 2012, 18, 323-324.	0.7	6
58	Modelling the effects of cell-cycle heterogeneity on the response of a solid tumour to chemotherapy: Biological insights from a hybrid multiscale cellular automaton model. <i>Journal of Theoretical Biology</i> , 2012, 308, 1-19.	0.8	130
59	Mathematical Methods and Models in Biomedicine. <i>Lecture Notes on Mathematical Modelling in the Life Sciences</i> , 2013, , .	0.1	10

#	ARTICLE	IF	CITATIONS
60	Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. <i>Acta Neuropathologica Communications</i> , 2013, 1, 17.	2.4	17
61	Optimisation of Cancer Drug Treatments Using Cell Population Dynamics. <i>Lecture Notes on Mathematical Modelling in the Life Sciences</i> , 2013, , 265-309.	0.1	15
63	Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs – an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research. <i>Journal of Translational Medicine</i> , 2013, 11, 282.	1.8	135
64	From forest and agroecosystems to the microecosystems of the human body: what can landscape ecology tell us about tumor growth, metastasis, and treatment options?. <i>Evolutionary Applications</i> , 2013, 6, 82-91.	1.5	19
65	Evolutionary foundations for cancer biology. <i>Evolutionary Applications</i> , 2013, 6, 144-159.	1.5	168
66	The Hippo pathway and human cancer. <i>Nature Reviews Cancer</i> , 2013, 13, 246-257.	12.8	1,479
67	Guanidino Anthrathiophenediones as G-Quadruplex Binders: Uptake, Intracellular Localization, and Anti-Harvey-ras Gene Activity in Bladder Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2764-2778.	2.9	47
68	Cyclodextrin-based targeting strategies for tumor treatment. <i>Drug Delivery and Translational Research</i> , 2013, 3, 364-374.	3.0	18
69	Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, β -Cyclodextrin-Based Drug Complexes for Cancer Treatment. <i>PLoS ONE</i> , 2013, 8, e62289.	1.1	47
70	Genetic heterogeneity in breast cancer: the road to personalized medicine?. <i>BMC Medicine</i> , 2013, 11, 151.	2.3	47
71	Changing T-cell enigma: Cancer killing or cancer control?. <i>Cell Cycle</i> , 2013, 12, 3335-3342.	1.3	13
72	Metronomics in low and middle income countries: India showing the way!. <i>Indian Journal of Cancer</i> , 2013, 50, 112.	0.2	4
73	Aggressive Chemotherapy and the Selection of Drug Resistant Pathogens. <i>PLoS Pathogens</i> , 2013, 9, e1003578.	2.1	81
74	Populational adaptive evolution, chemotherapeutic resistance and multiple anti-cancer therapies. <i>ESAIM: Mathematical Modelling and Numerical Analysis</i> , 2013, 47, 377-399.	0.8	101
75	“Just Caring”: Can We Afford the Ethical and Economic Costs of Circumventing Cancer Drug Resistance?. <i>Journal of Personalized Medicine</i> , 2013, 3, 124-143.	1.1	14
76	A Composite Synergistic Systems Model for Exploring the Efficacies of Different Chemotherapeutic Strategies in Cancer. <i>Computational Biology Journal</i> , 2013, 2013, 1-26.	0.6	4
77	Estimating Dose Painting Effects in Radiotherapy: A Mathematical Model. <i>PLoS ONE</i> , 2014, 9, e89380.	1.1	54
78	Antineoplastic Effect of Decoy Oligonucleotide Derived from MGMT Enhancer. <i>PLoS ONE</i> , 2014, 9, e113854.	1.1	3

#	ARTICLE	IF	CITATIONS
79	â€œœl Have a Dreamâ€œ, Journal of Circulating Biomarkers, 2014, 3, 5.	0.8	0
80	The role of maintenance strategies in breast cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 152-156.	0.3	1
81	Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch. Frontiers in Oncology, 2014, 4, 76.	1.3	31
83	Can a minimal replicating construct be identified as the embodiment of cancer?. BioEssays, 2014, 36, 503-512.	1.2	18
84	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. Expert Opinion on Biological Therapy, 2014, 14, 1769-1781.	1.4	4
85	Tumors as chaotic attractors. Molecular BioSystems, 2014, 10, 172-179.	2.9	17
86	Applying evolutionary biology to address global challenges. Science, 2014, 346, 1245993.	6.0	228
87	Chasing Mendel: five questions for personalized medicine. Journal of Physiology, 2014, 592, 2381-2388.	1.3	30
88	Metaphors in Nanomedicine: The Case of Targeted Drug Delivery. NanoEthics, 2014, 8, 1-17.	0.5	27
89	Evolutionary Rescue in Structured Populations. American Naturalist, 2014, 183, E17-E35.	1.0	90
90	Metronomics: towards personalized chemotherapy?. Nature Reviews Clinical Oncology, 2014, 11, 413-431.	12.5	263
91	An evolutionaryâ€œtype model for tumor immunotherapy. IFAC-PapersOnLine, 2015, 48, 575-580.	0.5	2
92	Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell International, 2015, 15, 71.	1.8	451
93	Evidence-based support for the use of proton pump inhibitors in cancer therapy. Journal of Translational Medicine, 2015, 13, 368.	1.8	50
94	Text Mining Applied to Electronic Medical Records. International Journal of E-Health and Medical Communications, 2015, 6, 1-18.	1.4	23
95	Recent highlights of experimental research for inhibiting tumor growth by using Chinese medicine. Chinese Journal of Integrative Medicine, 2015, 21, 727-732.	0.7	5
96	A switched systems approach to cancer therapy. , 2015, , .		5
97	Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Letters, 2015, 358, 100-106.	3.2	194

#	ARTICLE	IF	CITATIONS
98	Control vs. eradication: Applying infectious disease treatment strategies to cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 937-938.	3.3	35
99	Modeling the Effects of Space Structure and Combination Therapies on Phenotypic Heterogeneity and Drug Resistance in Solid Tumors. Bulletin of Mathematical Biology, 2015, 77, 1-22.	0.9	96
100	Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nature Reviews Genetics, 2015, 16, 459-471.	7.7	201
101	Estimation of Tumor Size Evolution Using Particle Filters. Journal of Computational Biology, 2015, 22, 649-665.	0.8	10
102	Memory versus effector immune responses in oncolytic virotherapies. Journal of Theoretical Biology, 2015, 377, 1-9.	0.8	22
103	Integrated PK-PD and agent-based modeling in oncology. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 179-189.	0.8	55
104	Epstein-Barr virus latent antigens EBNA3C and EBNA1 modulate epithelial to mesenchymal transition of cancer cells associated with tumor metastasis. Tumor Biology, 2015, 36, 3051-3060.	0.8	33
105	Application of Evolutionary Principles to Cancer Therapy. Cancer Research, 2015, 75, 4675-4680.	0.4	127
106	Of drug administration, war and oikos: mediating cancer with nanomedicines. Nanomedicine, 2015, 10, 3261-3274.	1.7	7
107	Cancer Ecology: Niche Construction, Keystone Species, Ecological Succession, and Ergodic Theory. Biological Theory, 2015, 10, 283-288.	0.8	20
109	Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine. Seminars in Cancer Biology, 2015, 35, 53-61.	4.3	67
110	Has Neo-Darwinism failed clinical medicine: Does systems biology have to?. Progress in Biophysics and Molecular Biology, 2015, 117, 107-112.	1.4	13
111	Philanthropic partnerships and the future of cancer research. Nature Reviews Cancer, 2015, 15, 125-129.	12.8	8
112	Physiologically Structured Cell Population Dynamic Models with Applications to Combined Drug Delivery Optimisation in Oncology. Mathematical Modelling of Natural Phenomena, 2016, 11, 45-70.	0.9	3
113	Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?. PLoS Computational Biology, 2016, 12, e1004689.	1.5	115
114	New paradigms in clonal evolution: punctuated equilibrium in cancer. Journal of Pathology, 2016, 240, 126-136.	2.1	69
115	Molecular mechanisms for tumour resistance to chemotherapy. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 723-737.	0.9	304
117	Excess of mutational jackpot events in expanding populations revealed by spatial Luria-Delbrück experiments. Nature Communications, 2016, 7, 12760.	5.8	97

#	ARTICLE	IF	CITATIONS
118	Darwinian Strategies to Avoid the Evolution of Drug Resistance During Cancer Treatment. , 2016, , 167-175.		1
119	Cancer tolerance, resistance, pathogenicity and virulence: deconstructing the disease state. Future Oncology, 2016, 12, 1369-1380.	1.1	2
120	â€œNo patient left behindâ€• an alternative to â€œthe War on Cancerâ€•metaphor. Medical Oncology, 2016, 33, 55.	1.2	8
121	Evolutionary Thinking in Medicine. , 2016, , .		7
122	Canine and feline lymphoma: challenges and opportunities for creating a paradigm shift. Veterinary and Comparative Oncology, 2016, 14, 1-7.	0.8	6
124	Systems Biology of Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2016, , .	0.8	7
125	Optimizing Chemotherapeutic Anti-cancer Treatment and the Tumor Microenvironment: An Analysis of Mathematical Models. Advances in Experimental Medicine and Biology, 2016, 936, 209-223.	0.8	7
126	Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 2627-2645.	1.1	69
127	Rethinking therapeutic strategies in cancer: Wars, fields, anomalies and monsters. Social Theory and Health, 2016, 14, 475-492.	1.0	1
128	Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-37.	0.4	4
129	Immunotherapy of melanoma: efficacy and mode of action. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-36.	0.4	16
130	Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Science Translational Medicine, 2016, 8, 327ra24.	5.8	260
131	A nonmainstream approach against cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 882-889.	2.5	24
132	Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. Journal of Neuro-Oncology, 2016, 126, 519-525.	1.4	105
133	Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment. Antioxidants and Redox Signaling, 2017, 26, 70-83.	2.5	26
134	Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering?. Seminars in Cancer Biology, 2017, 43, 111-118.	4.3	48
135	Cellular acidification as a new approach to cancer treatment and to the understanding and therapeutics of neurodegenerative diseases. Seminars in Cancer Biology, 2017, 43, 157-179.	4.3	59
136	Evolutionary rescue in randomly mating, selfing, and clonal populations. Evolution; International Journal of Organic Evolution, 2017, 71, 845-858.	1.1	31

#	ARTICLE	IF	CITATIONS
137	Hepatitis C Virus E1 protein promotes cell migration and invasion by modulating cellular metastasis suppressor Nm23-H1. <i>Virology</i> , 2017, 506, 110-120.	1.1	21
138	Cytokine-induced senescence for cancer surveillance. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 357-365.	2.7	14
139	Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?. <i>Cancer Letters</i> , 2017, 401, 74-80.	3.2	15
140	Recent highlights of Chinese medicine for advanced lung cancer. <i>Chinese Journal of Integrative Medicine</i> , 2017, 23, 323-330.	0.7	10
141	Evolutionary scalpels for dissecting tumor ecosystems. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 69-83.	3.3	10
142	Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies. <i>Cancer Research</i> , 2017, 77, 6717-6728.	0.4	28
143	Integrating Biological and Mathematical Models to Explain and Overcome Drug Resistance in Cancer, Part 2: from Theoretical Biology to Mathematical Models. <i>Current Stem Cell Reports</i> , 2017, 3, 260-268.	0.7	4
144	Radiotherapy-assisted tumor selective metronomic oral chemotherapy. <i>International Journal of Cancer</i> , 2017, 141, 1912-1920.	2.3	8
145	Neonicotinoid Seed Treatments: Limitations and Compatibility with Integrated Pest Management. <i>Agricultural and Environmental Letters</i> , 2017, 2, ael2017.08.0026.	0.8	49
146	Spatial competition constrains resistance to targeted cancer therapy. <i>Nature Communications</i> , 2017, 8, 1995.	5.8	94
147	Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. <i>Nature Communications</i> , 2017, 8, 1816.	5.8	412
148	Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer. <i>IEEE Transactions on Biomedical Engineering</i> , 2017, 64, 512-518.	2.5	23
149	MMP-TIMP interactions in cancer invasion: An evolutionary game-theoretical framework. <i>Journal of Theoretical Biology</i> , 2017, 412, 17-26.	0.8	46
150	A switching control law approach for cancer immunotherapy of an evolutionary tumor growth model. <i>Mathematical Biosciences</i> , 2017, 284, 40-50.	0.9	9
151	High-performance liquid chromatography coupled with tandem mass spectrometry technology in the analysis of Chinese Medicine Formulas: A bibliometric analysis (1997-2015). <i>Journal of Separation Science</i> , 2017, 40, 81-92.	1.3	24
152	Potential applications of nanoparticles in cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 63-74.	1.4	35
153	The anti-tumorigenic activity of A2M: A lesson from the naked mole-rat. <i>PLoS ONE</i> , 2017, 12, e0189514.	1.1	36
154	Coevolution of Tumor Cells and Their Microenvironment: Niche Construction in Cancer, 2017, , 111-117.		10

#	ARTICLE	IF	CITATIONS
155	Applying Tools From Evolutionary Biology to Cancer Research. , 2017, , 193-200.		5
156	Control in dormancy or eradication of cancer stem cells: Mathematical modeling and stability issues. Journal of Theoretical Biology, 2018, 449, 103-123.	0.8	11
157	Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer. Translational Oncology, 2018, 11, 732-742.	1.7	32
158	Cooperativity Principles in Self-Assembled Nanomedicine. Chemical Reviews, 2018, 118, 5359-5391.	23.0	129
159	The Evolution and Ecology of Resistance in Cancer Therapy. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a033415.	2.9	114
160	A target and nontarget strategy for identification or characterization of the chemical ingredients in Chinese herb preparation Shuangâ€Huangâ€Lian oral liquid by ultraâ€performance liquid chromatographyâ€quadrupole timeâ€ofâ€flight mass spectrometry. Biomedical Chromatography, 2018, 32, e4110.	0.8	35
161	Putting evolution in elimination: Winning our ongoing battle with evolving malaria mosquitoes and parasites. Evolutionary Applications, 2018, 11, 415-430.	1.5	49
162	Simultaneous Model Selection and Model Calibration for the Proliferation of Tumor and Normal Cells During In Vitro Chemotherapy Experiments. Journal of Computational Biology, 2018, 25, 1285-1300.	0.8	2
163	Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. Journal of Theoretical Biology, 2018, 459, 67-78.	0.8	87
164	An ecosystem framework for understanding and treating disease. Evolution, Medicine and Public Health, 2018, 2018, 270-286.	1.1	11
165	The importance of chaotic attractors in modelling tumour growth. Physica A: Statistical Mechanics and Its Applications, 2018, 507, 268-277.	1.2	18
166	A new conceptual framework for the therapy by optimized multidimensional pulses of therapeutic activity. The case of multiple myeloma model. Journal of Theoretical Biology, 2018, 454, 292-309.	0.8	0
167	Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. Journal of Theoretical Biology, 2018, 455, 249-260.	0.8	55
168	Signaling Pathways in Thyroid Cancer. Vitamins and Hormones, 2018, 106, 501-515.	0.7	12
169	An Analytical Approach for the Determination of Chemotherapeutic Drug Application Trade-Offs in Leukemia. Communications in Computer and Information Science, 2018, , 390-404.	0.4	0
170	How combination therapies shape drug resistance in heterogeneous tumoral populations. Letters in Biomathematics, 2018, 5, S160-S177.	0.3	3
171	Elimination plus Transformationâ€Chinese and Western Medicine Integration Brings Hope to Protracted War on Cancer. Chinese Journal of Integrative Medicine, 2018, 24, 563-567.	0.7	1
172	Optimizing Cancer Treatment Using Game Theory. JAMA Oncology, 2019, 5, 96.	3.4	136

#	ARTICLE	IF	CITATIONS
173	Evolution of cancer cell populations under cytotoxic therapy and treatment optimisation: insight from a phenotype-structured model. <i>ESAIM: Mathematical Modelling and Numerical Analysis</i> , 2019, 53, 1157-1190.	0.8	31
175	Aggressive or moderate drug therapy for infectious diseases? Trade-offs between different treatment goals at the individual and population levels. <i>PLoS Computational Biology</i> , 2019, 15, e1007223.	1.5	11
176	Nonlinear adaptive control of competitive release and chemotherapeutic resistance. <i>Physical Review E</i> , 2019, 99, 022404.	0.8	27
177	Multi-stage models for the failure of complex systems, cascading disasters, and the onset of disease. <i>PLoS ONE</i> , 2019, 14, e0216422.	1.1	13
178	Folic acid-modified β -cyclodextrin nanoparticles as drug delivery to load DOX for liver cancer therapeutics. <i>Soft Materials</i> , 2019, 17, 437-447.	0.8	31
179	Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging. <i>Nanotheranostics</i> , 2019, 3, 223-235.	2.7	28
180	Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy. <i>Clinical Cancer Research</i> , 2019, 25, 4413-4421.	3.2	85
181	Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. <i>Frontiers in Physics</i> , 2019, 7, .	1.0	3
182	Polytherapy and Targeted Cancer Drug Resistance. <i>Trends in Cancer</i> , 2019, 5, 170-182.	3.8	183
183	Resistance games. <i>Nature Ecology and Evolution</i> , 2019, 3, 336-337.	3.4	19
184	Optimal Control for Cancer Chemotherapy under Tumor Heterogeneity. , 2019, , .		1
185	Time scales and wave formation in non-linear spatial public goods games. <i>PLoS Computational Biology</i> , 2019, 15, e1007361.	1.5	8
186	Utilization of optically induced dielectrophoresis in a microfluidic system for sorting and isolation of cells with varied degree of viability: Demonstration of the sorting and isolation of drug-treated cancer cells with various degrees of anti-cancer drug resistance gene expression. <i>Sensors and Actuators B: Chemical</i> , 2019, 283, 621-631.	4.0	44
187	Preparation and characterization of folic acid functionalized bioactive glass for targeted delivery and sustained release of methotrexate. <i>Journal of Biomedical Materials Research - Part A</i> , 2019, 107, 319-329.	2.1	5
188	Cooperation among cancer cells: applying game theory to cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 110-117.	12.8	118
189	Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy. <i>International Journal of Cancer</i> , 2019, 144, 2169-2180.	2.3	22
190	Range Expansion Theories Could Shed Light on the Spatial Structure of Intra-tumour Heterogeneity. <i>Bulletin of Mathematical Biology</i> , 2019, 81, 4761-4777.	0.9	6
191	Kaposi sarcoma-associated herpes virus (KSHV) latent protein LANA modulates cellular genes associated with epithelial-to-mesenchymal transition. <i>Archives of Virology</i> , 2019, 164, 91-104.	0.9	6

#	ARTICLE	IF	CITATIONS
192	Eradicating Metastatic Cancer and the Eco-Evolutionary Dynamics of Anthropocene Extinctions. <i>Cancer Research</i> , 2020, 80, 613-623.	0.4	37
193	How Should Cancer Models Be Constructed?. <i>Cancer Control</i> , 2020, 27, 107327482096200.	0.7	17
194	Modeling a cancerous tumor development in a virtual patient suffering from a depressed state of mind: Simulation of somatic evolution with a customized genetic algorithm. <i>BioSystems</i> , 2020, 198, 104261.	0.9	4
195	Integrating evolutionary dynamics into cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 675-686.	12.5	111
196	Evolutionary strategies to overcome cancer cell resistance to treatment. , 2020, , 691-703.		1
197	miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers. <i>Cancer Letters</i> , 2020, 492, 185-196.	3.2	11
198	The Intersection of Regional Anesthesia and Cancer Progression: A Theoretical Framework. <i>Cancer Control</i> , 2020, 27, 107327482096557.	0.7	4
199	Can Environmental Manipulation Help Suppress Cancer? Non-Linear Competition Among Tumor Cells in Periodically Changing Conditions. <i>Advanced Science</i> , 2020, 7, 2000340.	5.6	7
200	Modifying Adaptive Therapy to Enhance Competitive Suppression. <i>Cancers</i> , 2020, 12, 3556.	1.7	33
201	Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations. <i>PLoS Biology</i> , 2020, 18, e3000713.	2.6	50
202	Resistance is not the end: lessons from pest management. <i>Cancer Control</i> , 2020, 27, 107327482092254.	0.7	4
203	Exploiting collateral sensitivity controls growth of mixed culture of sensitive and resistant cells and decreases selection for resistant cells in a cell line model. <i>Cancer Cell International</i> , 2020, 20, 253.	1.8	17
204	Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 471-486.	2.3	50
205	Dark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation. <i>Trends in Cancer</i> , 2020, 6, 419-431.	3.8	48
206	Cancer therapy: Attempt cure or manage drug resistance?. <i>Evolutionary Applications</i> , 2020, 13, 1660-1672.	1.5	27
207	Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines. <i>Cancers</i> , 2020, 12, 404.	1.7	39
208	In the Absence of a TCR Signal IL-2/IL-12/18-Stimulated CD8 ⁺ T Cells Demonstrate Potent Anti-Tumoral Function Through Direct Killing and Senescence Induction in Cancer Cells. <i>Cancers</i> , 2020, 12, 130.	1.7	15
209	Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. <i>Pituitary</i> , 2020, 23, 359-366.	1.6	25

#	ARTICLE	IF	CITATIONS
210	Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy. <i>Cancer Research</i> , 2021, 81, 1135-1147.	0.4	71
211	The ecology of cancer differentiation therapy. <i>Journal of Theoretical Biology</i> , 2021, 511, 110552.	0.8	7
212	Tumor Profiling at the Service of Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 595613.	1.3	9
213	Unlocking the Mystery of the Therapeutic Effects of Chinese Medicine on Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 601785.	1.6	18
214	Do mechanisms matter? Comparing cancer treatment strategies across mathematical models and outcome objectives. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 6305-6327.	1.0	8
216	Computational Prediction of Hot Spots and Binding Site of Inhibitor NSC23766 on Rac1 Binding With Tiam1. <i>Frontiers in Chemistry</i> , 2020, 8, 625437.	1.8	9
217	Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. <i>Npj Breast Cancer</i> , 2021, 7, 26.	2.3	7
218	A theoretical analysis of tumour containment. <i>Nature Ecology and Evolution</i> , 2021, 5, 826-835.	3.4	54
219	Induction of apoptosis by Kola nut extract as a recent and promising treatment strategy for Leukemia. <i>Revista Bionatura</i> , 2021, 6, 1725-1732.	0.1	1
220	The therapeutic landscape of hepatocellular carcinoma. <i>Med</i> , 2021, 2, 505-552.	2.2	20
221	Metronomic Chemotherapy Modulates Clonal Interactions to Prevent Drug Resistance in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2239.	1.7	15
222	Natural Killer Cells Recruitment in Oncolytic Virotherapy: A Mathematical Model. <i>Bulletin of Mathematical Biology</i> , 2021, 83, 75.	0.9	10
224	Collapse of Intra-Tumor Cooperation Induced by Engineered Defector Cells. <i>Cancers</i> , 2021, 13, 3674.	1.7	7
225	Loss of smarcad1a accelerates tumorigenesis of malignant peripheral nerve sheath tumors in zebrafish. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 743-761.	1.5	3
226	Evolutionary Dynamics of Treatment-Induced Resistance in Cancer Informs Understanding of Rapid Evolution in Natural Systems. <i>Frontiers in Ecology and Evolution</i> , 2021, 9, .	1.1	9
227	The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer. <i>Dynamic Games and Applications</i> , 2022, 12, 313-342.	1.1	42
228	Cancer Stem Cells and Tumor Dormancy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 734, 55-71.	0.8	19
230	Toxicology, Safety and Herbâ€“drug Interactions in Cancer Therapy. , 2010, , 293-340.		1

#	ARTICLE	IF	CITATIONS
231	The beginning of the end for conventional RECIST “ novel therapies require novel imaging approaches. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 442-458.	12.5	97
232	Pseudo-branched polyester copolymer: an efficient drug delivery system to treat cancer. <i>Biomaterials Science</i> , 2020, 8, 1592-1603.	2.6	3
239	The Evolution and Ecology of Resistance in Cancer Therapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a040972.	2.9	30
241	Tumour Cell Heterogeneity. <i>F1000Research</i> , 2016, 5, 238.	0.8	91
242	How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient. <i>PLoS Biology</i> , 2017, 15, e2001110.	2.6	103
243	Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. <i>Oncoscience</i> , 2014, 1, 777-802.	0.9	198
244	Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. <i>Oncotarget</i> , 2016, 7, 62177-62193.	0.8	23
245	Peptide derived peptides affect colorectal cancer cell lines resistance and tumour re-growth capacity. <i>Oncotarget</i> , 2019, 10, 2973-2986.	0.8	5
246	Applied mathematics and nonlinear sciences in the war on cancer. <i>Applied Mathematics and Nonlinear Sciences</i> , 2016, 1, 423-436.	0.9	30
247	Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 479-484.	0.5	15
248	Designing proliferating cell population models with functional targets for control by anti-cancer drugs. <i>Discrete and Continuous Dynamical Systems - Series B</i> , 2013, 18, 865-889.	0.5	18
249	Dynamics and optimal control of chemotherapy for low grade gliomas: Insights from a mathematical model. <i>Discrete and Continuous Dynamical Systems - Series B</i> , 2016, 21, 1895-1915.	0.5	8
250	An elementary approach to modeling drug resistance in cancer. <i>Mathematical Biosciences and Engineering</i> , 2010, 7, 905-918.	1.0	52
251	Optimal control of a mathematical model for cancer chemotherapy under tumor heterogeneity. <i>Mathematical Biosciences and Engineering</i> , 2016, 13, 1223-1240.	1.0	27
252	On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach. <i>Mathematical Biosciences and Engineering</i> , 2017, 14, 217-235.	1.0	20
253	An Evolutionary Approach for Personalized Therapy in Multiple Myeloma. <i>Applied Mathematics</i> , 2016, 07, 159-169.	0.1	5
254	Using Systems Biology to Understand Cancer as an Evolutionary Process. <i>Journal of Evolutionary Medicine</i> , 2014, 2, 1-8.	0.5	3
255	Um modelo matemático em quimioterapia. <i>TeMa</i> , 2012, 13, 01-12.	0.1	6

#	ARTICLE	IF	CITATIONS
256	Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients. <i>Journal of Cancer Therapeutics & Research</i> , 2012, 1, 32.	1.2	25
257	Contradictory Relationships between Cancer and Normal Cells and Implications for Anti-cancer Therapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5143-5147.	0.5	1
258	Dynamics of preventive vs post-diagnostic cancer control using low-impact measures. <i>ELife</i> , 2015, 4, e06266.	2.8	8
259	Molecular Evolutionary Process of Advanced Gastric Cancer During Sequential Chemotherapy Detected by Circulating Tumor DNA. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
261	<i>Synthetic Biology and Perspectives</i> . , 2011, , 449-469.		0
262	<i>Introduction to Systems Approaches to Cancer</i> . , 2011, , 3-27.		0
263	<i>Cell-Based Models of Tumor Angiogenesis</i> . , 2012, , 135-150.		2
264	<i>Mathematical Modeling of Cancer Cells Evolution Under Targeted Chemotherapies</i> . <i>Springer Proceedings in Mathematics and Statistics</i> , 2014, , 81-89.	0.1	0
265	<i>Acquired Immunity: Fungal Infections</i> . , 0, , 289-299.		0
273	Study of metronomic chemotherapy in cancer patients at a tertiary care center in South India. <i>Clinical Cancer Investigation Journal</i> , 2019, 8, 192.	0.2	0
276	<i>The Integrative Model of Circulation: A Synthesis</i> . , 2020, , 343-369.		0
281	<i>Healthcare Reform. Advances in Healthcare Information Systems and Administration Book Series</i> , 2020, , 144-166.	0.2	0
282	Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach. <i>Scientific Reports</i> , 2021, 11, 21475.	1.6	29
285	Is the Fixed Periodic Treatment Effective for the Tumor System without Complete Information?. <i>Cancer Management and Research</i> , 2021, Volume 13, 8915-8928.	0.9	2
289	The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response. <i>PLoS Computational Biology</i> , 2022, 18, e1009919.	1.5	4
290	Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses. <i>Cancers</i> , 2022, 14, 1364.	1.7	13
291	Multilevel Mesoscale Complexities in Mesoregimes: Challenges in Chemical and Biochemical Engineering. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2022, 13, 431-455.	3.3	3
292	The 50-Year War on Cancer Revisited: Should We Continue to Fight the Enemy Within?. <i>Journal of Cancer Prevention</i> , 2021, 26, 219-223.	0.8	7

#	ARTICLE	IF	CITATIONS
293	Conditional prediction of consecutive tumor evolution using cancer progression models: What genotype comes next?. PLoS Computational Biology, 2021, 17, e1009055.	1.5	11
294	Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Communications Medicine, 2022, 2, .	1.9	26
295	Tumour immunotherapy: lessons from predatorâ€“prey theory. Nature Reviews Immunology, 2022, 22, 765-775.	10.6	41
296	Normal Science and Limits on Knowledge: What We Seek to Know, What We Choose Not to Know, What We Donâ€™t Bother Knowing. , 2010, 77, 997-1010.		7
297	Mathematical Oncology to Cancer Systems Medicine: Translation from Academic Pursuit to Individualized Therapy with MORA. Current Cancer Therapy Reviews, 2022, 18, .	0.2	0
298	Dynamics of a Mathematical Model of Cancer and Immunoediting Scenarios Under the Variation of the Immune Cell Activation Rate. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 2022, 32, .	0.7	1
299	In Silico Investigations of Multi-Drug Adaptive Therapy Protocols. Cancers, 2022, 14, 2699.	1.7	10
300	Delaying Emergence of Resistance to KRAS Inhibitors with Adaptive Therapy: â€œTreatment-to-Containâ€• Instead of â€œTreatment-to-Cureâ€•. Oncologie, 2022, 24, 185-194.	0.2	1
301	Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer. Oncology Research and Treatment, 2022, 45, 681-692.	0.8	7
302	Insight of pancreatic cancer: recommendations for improving its therapeutic efficacy in the next decade. Journal of Pancreatology, 2022, 5, 58-68.	0.3	1
304	A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers, 2022, 14, 5225.	1.7	7
305	Ecology and games in cancer: new insights into the disease. Pathologica, 2022, 114, 347-351.	1.3	0
306	The Tumor Invasion Paradox in Cancer Stem Cell-Driven Solid Tumors. Bulletin of Mathematical Biology, 2022, 84, .	0.9	2
308	Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?. Expert Review of Anticancer Therapy, 0, , .	1.1	0
309	Lactiseibacillus rhamnosus Probio-M9-Driven Mouse Mammary Tumor-Inhibitory Effect Is Accompanied by Modulation of Host Gut Microbiota, Immunity, and Serum Metabolome. Nutrients, 2023, 15, 5.	1.7	7
311	The future of evolutionary medicine: sparking innovation in biomedicine and public health. , 2023, 1, .		11
325	Tumor Ecosystem-Directed Therapeutic Strategies. , 2023, , 675-701.		0